Clinical Trials Logo

Clinical Trial Summary

Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05226780
Study type Interventional
Source Neurocrine Biosciences
Contact
Status Enrolling by invitation
Phase Phase 2
Start date July 12, 2022
Completion date March 2026